Wednesday, February 26, 2014

AND IT KEEPS HAPPENING FOR THE" WONDER" DRUG

FROM MEDSCAPE:

"The FDA has given accelerated approval to ibrutinib (Imbruvica) for treating CLL in patients who have undergone at least 1 previous therapy. Approval was granted based on the findings of a clinical study of 48 previously treated patients who were diagnosed with CLL, on average, 6.7 years before the study. The patients had an overall response rate of nearly 58%, with a duration of response from 5.6 to 24.2 months. The most common adverse effects observed in the study included thrombocytopenia, diarrhea, bruising, neutropenia, anemia, and upper respiratory tract infection. Ibrutinib was also approved for treating mantle cell lymphoma in 2013."

================================THIS DRUG IS JUST WONDERFUL, ATTESTING TO THE STRENGTH AND IMPORTANCE OF THIS RECEPTOR IN LYMPHOCYTE RELATED PROLIFERATIONS.....=================
Post a Comment